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Summary (100) 
This study compares patients with venous thromboembolism (VTE) to non-VTE patients using a 
biomarker of clot microstructure (df) and clot formation time (TGP). df was the only marker that 
identified a significant difference (p<0.001) between the VTE (n=60) and non-VTE cohorts 
(n=69). The ‘abnormal’ clot microstructures observed in the VTE patients suggests either 
inadequate response to anticoagulant therapy, or the presence of a procoagulant state not detected 
by other markers of coagulation (i.e. INR). Furthermore, elevated values of df in first time VTE 
patients who later develop a secondary event indicates that df may identify those at risk of 
recurrence.  
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Introduction 
Venous thromboembolism (VTE) is a major health problem worldwide with an annual incidence 
of around 1 per 1000 person-years (Silverstein et al, 1998; Heit et al, 2006). The management of 
VTE includes the administration of oral anticoagulants such as warfarin. Warfarin dosage is 
monitored using the International Normalised Ratio (INR) however recurrent embolic events in 
patients who are fully anticoagulated according to their INR remain problematic (Kearon et al, 
2008; Thachil, 2012).   
 
Clots with abnormal microstructures and viscoelastic properties have been reported in patients 
with VTE (Undas et al, 2009; Martinez et al, 2014). A biomarker that can quantify abnormal clot 
microstructure could identify subjects at risk of thrombotic events and improve current 
management strategies by providing a more individualized therapeutic approach.  
 
 
This paper reports an observational cohort study that differentiates VTE from non-VTE patients 
by using a new biomarker based on viscoelastic measurements of clotting blood at the Gel Point 
(GP). The GP measurement has been validated in healthy subjects (Evans et al, 2010) and 
quantifies both clot microstructure in terms of its fractal dimension, df, and clot formation time 
(TGP). In contrast to standard coagulation assays this technique uses unadulterated whole blood in 
a near patient setting. 
  
Methods 
Patients 
This is an observational cohort study approved by the local Research Ethics Committee (South 
West Wales REC 6). Patients routinely attending the anticoagulation clinic at a large UK teaching 
hospital were recruited following informed written consent. Patients were excluded if they were 
on anti-platelet therapy or acutely unwell. A 20 ml venous blood sample was obtained for GP 
measurements, Standard Coagulation Markers, Thrombin Generation, t-PA-PAI 1, D-dimer and 
Thromboelastography. All assays were calibrated and quality control performed according to 
manufacturer’s instructions.  
 
GP measurements were obtained by reproducing the methodology reported in a previous study 
(Lawrence et al, 2014). A 6.6 ml aliquot of whole blood was loaded into a double-gap concentric 
cylinder measuring geometry of an AR-G2 (TA Instruments, USA) controlled-stress rheometer (at 
37°C ± 0.1ºC) and measurements were started immediately.  
 
A 4.5 ml aliquot of blood was used to obtain standard coagulation markers including; Prothrombin 
Time (PT) and INR, activated partial thromboplastin time (APTT) and Clauss fibrinogen, all 
measured using a Sysmex CA1500 analyzer within 2 hrs of collection. All reagents were obtained 
from Siemens, (Frimley, UK). Thrombin generation was performed using the TGA assay and 
associated software (Technoclone Diagnostics, Austria). In summary 40µL of citrated plasma was 
dispensed into an ELISA plate at 37ºC (NUNC F16 maxisorp black fluorescence plates, Pathway 
Diagnostics, UK).10 µL tissue factor (Technoclone Diagnostics, Austria) was added (final 
concentration 5pM), followed by 50µL of fluorogenic substrate 1mM Z-G-G-R-AMC 
(Technoclone Diagnostics, Austria).The fibrinolytic marker t-PA-PAI 1 complex was assessed 
using ELISA assay (Hyphen Biomed, Quadratech, UK). D-Dimers were measured using the 
TriniLIA Auto-Dimer® turbidimetric assay with a Sysmex CA1500 analyzer (Siemens, UK). 
Another 360l aliquot of whole blood was immediately analyzed using thromboelastography 
(TEG®- Hemoscope 3000). R-time, MA (maximum amplitude), and TMA (time to maximum 
amplitude) were recorded.  
 
Results are reported as mean (±SD) unless otherwise stated. Pearson correlation coefficients, two-
sample t-test and Mann-Whitney U test were used for analysis. Data was deemed significant when 
p<0.05. Statistical analysis was performed using Minitab version 16 software (Havertown, USA).  
Results and Discussion 
Patient recruitment and clinical details 
Patients were divided into a VTE cohort (n=60), those receiving warfarin for lower limb deep 
venous thrombosis (DVT) or pulmonary embolism (PE), and a non-VTE cohort (n=68) for patients 
receiving warfarin for other reasons (atrial fibrillation and heart valve disease). The VTE cohort 
contained 16 single and 44 recurrent VTE, 27 of which were due to DVT and 33 to PE with or 
without DVT. The non-VTE cohort contained 48 atrial fibrillation and 20 valve replacements. We 
found that all markers with the exception of df show no significant differences between the VTE 
and non-VTE cohorts (Table 1). The time in therapeutic range (TTR) (Rosendaal et al, 1993), for 
the VTE was 60.5% (IQR 51.7-72.7) and for non-VTE was 65.6% (IQR 55.2-74.6) was not 
significantly different (p=0.248).All analysis was first performed for all patients in a cohort then 
repeated for only those within therapeutic INR range, a similar trend was observed in both cases. 
 
A significant difference in df is found between the VTE group and the non-VTE group. 
Previously the df for non-anticoagulated healthy blood was found to be 1.74±0.07, where 
progressive in-vitro anticoagulation lowered the value (1.55 < df < 1.74) (Evans et al, 2010). It 
was expected that warfarin would cause a reduction in df, which it did in the non-VTEs 
(df=1.69±0.046).In contrast the df in the VTE cohort is essentially indistinguishable from the 
healthy cohort despite full anticoagulation (1.73±0.055) a value significantly different from the 
non-VTEs (p=0.002). Interestingly INR values of VTEs and non-VTEs are similar (INR= 2.7±1.09 
and 2.7±0.73 respectively). This suggests that the VTE patients’ anticoagulation may be sub-
therapeutic, at least in the context that clot microstructure is not being sufficiently altered. Whilst 
warfarin may prolong coagulation, clinically this effect can be sub-optimal with some patients still 
developing thrombosis (Kearon et al, 2008; Thachil, 2012). It is possible that increased values of 
df are the result of an increase in thrombotic potential, one that is not adequately regulated by 
warfarin.  
 
Time based markers of coagulation revealed no significant difference between the VTE and non-
VTE cohorts.  
No significant correlation between df and the standard time based markers of coagulation (INR -
r=0.006, p=0.9) was found.  In contrast the GP derived time based marker, TGP, was negatively 
correlated with df (r=-0.352, p< 0.001) as found in a previous study (Evans et al, 2010).
  However, 
all time based markers measured herein, show no significant difference between VTE and non-
VTE (Table 1). Current anticoagulant monitoring is widely performed using time based 
assessments of coagulation, from a clinical perspective the findings of this study suggests 
measuring clot microstructure provides additional information which could improve therapeutic 
management of VTE patients. 
 
df is a potential indicator of increased risk of VTE recurrence in patients with a first time VTE 
The VTE group contained 16 single VTEs (s-VTE) and 44 recurrent VTEs (r-VTE), where the 
value of df for the r-VTE (df =1.74±0.049) was significantly higher than the s-VTE (df=1.71±0.060) 
(p=0.001). Furthermore, 3 of the 16 s-VTE patients at the time of the GP test later developed into 
r-VTE (within a 2 year follow up), each having a relatively high value of df (1.74, 1.75 &1.78) in 
comparison to the mean of the s-VTE patients. Increases in df would be expected to have significant 
consequences in terms of clot functionality, such as a denser structure with reduced porosity and 
increased clot elasticity or strength. Features such as these could lead to ineffective fibrinolysis 
and increased risks of embolization (Mills et al, 2002; Weisel et al, 2013).  These findings suggest 
that df may be a potential indicator of increased risk of VTE recurrence. 
 
Small changes in df correspond to substantial changes in clot mass 
It is important to recognize what these differences in df represent in terms of the fibrin mass 
incorporated within the clot. Large amounts of mass M are required to produce small changes in 
df (Curtis et al, 2011), the non-linear relationship between M and df shown in Fig 1 revealing that 
a clot with df =1.69 (non-VTE group) has approximately half the mass of a clot for which df = 1.73 
(VTE group). Strikingly, for df = 1.86 (the highest single value recorded for the VTE cohort), more 
than 40-times more fibrin mass is incorporated within the clot than at df = 1.59 (the lowest 
recorded, for a member of the non-VTE group). From a clinical perspective, the incorporation of 
substantial additional mass within the incipient clot is significant, given its role as a microstructural 
template for clot development (Curtis et al, 2013). 
 
In conclusion while the VTE and non-VTE groups are not age and sex matched and do not directly 
investigate patients’ risk of thromboembolic disease, the study reveals that VTE patients 
anticoagulated with warfarin, produce ‘abnormal’ clot microstructures, when compared to another 
patient group with similar INR. This suggests either a less effective response of VTE patients to 
anticoagulant therapy, or the presence of a more procoagulant state not detected by current tests 
(i.e. INR), or both. It follows that the ability to detect abnormalities in clot microstructure using 
whole blood as determined by df may complement (or even replace) the available routine clotting 
tests, which will allow the clinician to develop and assess new anticoagulation regimes in the 
treatment of thromboembolic conditions. Furthermore, this study highlights that increased values 
of df in patients who have suffered a first time VTE may predict risk of recurrence.  A larger 
prospective study will explore these potential clinical implications. 
 
Acknowledgements 
This work was supported by grants from the National Institute of Social Care and Health Research 
and the Engineering and Physical Sciences Research Council. 
 
Author Contributions 
MJL, SP, WA, GM recruited patients. MJL, KH, SJD performed experiments. MRB, DJC 
performed computational analysis. AS, GM, WA, LAD collected patient data. MJL, AS, PAE, JW, 
PRW,RHKM analyzed and interpreted the data. PAE designed the research. All authors reviewed 
and approved the article.  
 
Competing Interests 
The authors have no competing interests. 
 
 
 
 
  
References 
Collet, J.P., Park, D., Lesty, C., Soria, J., Soria, C., Montalescot, G. & Weisel, J.W. (2000) 
Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic 
and structural approaches by confocal microscopy. Arteriosclerosis, Thrombosis and Vascular 
Biology, 20, 1354-1361. 
 
Curtis, D.J., Brown, M.R., Hawkins, K., Evans, P.A., Lawrence, M.J., Rees, P. & Williams, P.R. 
(2011) Rheometrical and molecular dynamics simulation studies of incipient clot formation in 
fibrin-thrombin gels: An activation limited aggregation approach. Journal of Non-Newtonian 
Fluid Mechanics, 166, 932-928. 
 
Curtis, D.J.,   Williams, P.R.,   Badiei, N., Campbell, A.I., Hawkins, K., Evans, P.A. & Brown, 
M.R. (2013) A study of microstructural templating in fibrin–thrombin gel networks by spectral and 
viscoelastic analysis. Soft Matter, 9, 4883-4889. 
 
Evans, P.A., Hawkins, K., Morris, R.H.K., Thirumalai, N., Munro, R., Wakeman, L., Lawrence, 
M.J. & Williams, P.R. (2010) Gel point and fractal microstructure of incipient clots are significant 
new markers of hemostasis for healthy and anticoagulated blood. Blood, 116, 3341-3344. 
 
Heit, J., Petterson, T., Farmer, S., Bailey, K. & Melton, L. (2006) Trends in Incidence of deep vein 
thrombosis and pulmonary embolism: a 35-year population-based study. Blood, 108, 430. 
 
Kearon, C., Julian, J.A.,  Kovacs, M.J.,  Anderson, D.R., Wells, P., MacKinnon, B.,  Weitz, 
J.I.,  Crowther, M.A., Dolan, S., Turpie, A.G., Geerts, W., Solymoss, S., van Nguyen, P., Demers, 
C., Kahn, S.R., Kassis, J., Rodger, M., Hambleton, J., Gent, M. &  Ginsberg, J.S. (2008) Influence 
of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a 
randomized trial. Blood, 112, 4432-4436. 
 
Lawrence, M.J., Kumar, S., Hawkins, K., Boden, S., Rutt, H., Mills, G., Sabra, A., Morris, R.H.K., 
Davidson, S.J., Badiei, N., Brown, M.R., Williams, P.R. & Evans, P.A. (2014) A new structural 
biomarker that quantifies and predicts changes in clot strength and quality in a model of 
progressive haemodilution. Thrombosis Research, 134 , 488-494. 
 
Martinez, M.R., Cuker, A., Mills, A.M., Crichlow, A., Lightfoot, R.T., Chernysh, I.N., 
Nagaswami, C., Weisel, J.W. & Ischiropoulos, H. (2014) Enhanced lysis and accelerated 
establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism. 
American Journal of Physiology - Lung Cellular and Molecular Physiology. 306, L397–L404. 
 
Mills, J.D., Ariëns, R.A.S., Mansfield, M.W. & Gran, P.J. (2002) Altered fibrin clot structure in 
the healthy relatives of patients with premature coronary artery disease. Circulation, 106, 1938-
1942. 
 
Rosendaal, F.R., Cannegieter, S.C., van der Meer, F.J. & Briët, E. (1993) A method to determine 
the optimal intensity of oral anticoagulant therapy.  Thrombosis and Haemostasis, 69, 236-239. 
 
Silverstein, M., Heit, J., Mohr, D., Petterson, T., O’Fallon, W. & Melton, L. (1998) Trends in the 
incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based, cohort 
study. Archives of Internal Medicine, 158, 585–593. 
 
Thachil J. (2012) Recurrent venous thromboembolism while on anticoagulant therapy. Blood 
Reviews, 26, 175–181. 
 
Undas, A., Zawilska, K., Ciesla-Dul, M., Lehmann-Kopydlowska, A., Skubiszak, A., Ciepluch, 
K. & Tracz, W. (2009) Altered fibrin clot structure/function in patients with idiopathic venous 
thromboembolism and in their relatives. Blood, 114, 4272-4278 
 
Weisel, J.W. & Litvinov, R.I. (2013) Mechanisms of fibrin polymerization and clinical 
implications. Blood, 121, 1712-1719. 
 
 
 
 
  
 
  
Fig 1 – Graph illustrating the non-linear relationship between the fractal dimension, df and the 
amount of mass, incorporated within the fractal structure. The mass value on the y-axis is 
normalised with respect to the healthy index value of df =1.74 (circle). Illustrations of different 
incipient clot microstructures at particular values of df are provided, corresponding to the range of 
df values obtained in this study. When compared with the healthy index value, a clot for which df 
=1.60 (cross) would be characterised by reduced mechanical strength (elasticity) and a more open, 
porous network structure – features typically associated with hypocoagulable states. Conversely, 
a clot for which df =1.80 (square) would be mechanically far stronger, with a more compact 
microstructure corresponding to a hypercoagulable state. 
 
 
 
 
 
 
 
 
 
 
  
 ALL Patients VTE non-VTE 
p value (VTE 
vs non-VT) 
Patient demographics†   
Mean (±SD)    
Age (years) 63.3±12.5 57.1±12.6 67.9±10.5 0.02 
Male (%) 86/128 (67.2%) 35/60 (59.6%) 51/68 (75.7%) 0.37 
     
Gel Point†    
df 1.72±0.053 1.73±0.055 1.69±0.046 0.002 
TGP 373±150 366±135 384±164 0.49 
     
General Markers†   
INR 2.7 (±0.89) 2.7 (±1.09) 2.7 (±0.73) 0.52 
APTT (sec) 37.1 (±5.15) 37.6 (±7.14) 36.2 (±4.25) 0.17 
Fibrinogen(Clauss) (g/l) 3.5 (±0.68) 3.4 (±0.67) 3.6 (±0.70) 0.22 
     
Thromboelastography†   
R-time (min) 19.2±9.5 19.0±9.1 19.4±10.7 0.84 
MA (mm) 45.9±119 45.6±11.2 46.0±13.2 0.88 
TMA (min) 52.3±21.8 53.1±19.0 51.9±23.6 0.88 
     
Thrombin Generation ‡   
Median (range)    
TGA (nM) 62 (41-85) 61 (50-84) 67 (49-95.2) 0.44 
     
Fibrinolytic Markers‡   
t-PA-PAI (mg/mL) 2.0 (0.86-3.03) 1.5 (1.56-2.00) 2.2 (1.43-3.17) 0.21 
D-Dimer 20 (0-51) 23 (0-26) 25 (0-59) 0.61 
Table 1:  Patient Demographics, Baseline Characteristics and Gel Point Measurements for 
all patients and the two cohorts: VTE and non-VTE groups. Showing p values for †two 
sample t-test and ‡Mann-Whitney U test between the VTE and non-VTE groups.  
 
